Medical Laboratory Analyses and Health Issues of Jeffrey Epstein: Analysis of the Declassified Documents

Abstract
In January 2026, the U.S. Department of Justice released more than 3.5 million pages of documents under the Epstein Files Transparency Act, including medical correspondence, laboratory reports, and financial records pertaining to Jeffrey Epstein for the period 2006–2019. These materials indicate chronic hypogonadism, recurrent sexually transmitted and parasitic infections, metabolic disturbances, and participation in experimental genetic studies. This article systematizes the available laboratory findings and clinical picture, demonstrating the potential of modern artificial intelligence tools for the early interpretation of multiparametric laboratory profiles.

Introduction
The 2026 release of the Epstein Files has provided unprecedented access to the medical data of one of the most controversial figures of recent decades. Although full medical records remain partially redacted to protect confidentiality, the available fragments (email correspondence, laboratory reports, invoices) make it possible to reconstruct key aspects of Jeffrey Epstein’s health status.

This analysis is conducted from the perspective of contemporary laboratory medicine and AI-driven biomarker interpretation. Aima Diagnostics is developing a platform capable of identifying complex patterns in laboratory profiles while accounting for demographic, clinical, and behavioral factors. The Epstein case illustrates how chronic abnormalities may remain undetected when conventional interpretation approaches are applied.

Data Sources and Methods
Data were extracted from the official portal of the U.S. Department of Justice, specifically from Data Sets 9–12 (2026 release).

Primary sources include:

• email correspondence with treating physicians (Dr. Bruce Moskowitz, Dr. Joseph Thakuria, and others);
• scanned copies of laboratory reports and invoices;
• documents related to the Harvard Personal Genome Project (PGP) and associated genetic testing.

Laboratory FindingsTable 1-3.
Key Laboratory Parameters (by period and test type)

Clinical Picture and Interpretation

Endocrine disorders
Persistently low total testosterone levels (<150 ng/dL over at least 10 years) are consistent with severe hypogonadism. Likely contributing factors include age-related androgen decline, compounded by obesity, chronic stress, and possible alcohol consumption.

Infectious pathology
Recurrent sexually transmitted infections (gonorrhea) and tropical parasitic diseases suggest high-risk sexual behavior and travel to endemic regions.

Metabolic and comorbid conditions
Dyslipidemia, back pain, limb numbness, and sleep disturbances (including sleep apnea) form a complex metabolic and neurological profile.


Personalized Interpretation in the Context of Aima Diagnostics

Aima Diagnostics applies multiparametric AI analysis of laboratory data, incorporating the following personalization factors:
Age — physiological annual testosterone decline of 0.8–2% after age 40
Ethnic/national background — men of South Asian descent typically have testosterone levels approximately 2 nmol/L lower than those of European ancestry

Lifestyle factors:

• Smoking — short-term elevation, long-term suppression of testosterone
• Chronic alcohol consumption — suppression of the hypothalamic–pituitary–gonadal axis (reduction of up to 12%)
• Physical activity — dose-dependent increase in testosterone levels
• Obesity (BMI >25 kg/m²) — reduction in testosterone by approximately 1.5–2 nmol/L

Medication use — influence of hormone therapy, antidepressants, opioids, etc.
Geographic factors — increased risk of parasitic infections in tropical regions


In Epstein’s case, integration of these variables could have generated a more accurate risk profile and supported timely interventions (dynamic monitoring, lifestyle modification, and early infection detection).


Ethical Considerations and Limitations

The documents reveal systematic breaches of medical confidentiality: laboratory results of female patients were reportedly shared with Epstein without informed consent. This underscores the critical importance of strict anonymization and privacy standards in modern AI-driven laboratory interpretation systems (Aima Diagnostics implements anonymization-by-design principles and full GDPR/EHDS compliance).

Limitations of the analysis include partial redaction of documents, the absence of complete medical records, and potential bias in correspondence.

Conclusion

The Jeffrey Epstein case illustrates the critical importance of deep and personalized interpretation of laboratory data in modern clinical practice. Chronic abnormalities that remained unaddressed for extended periods might have been identified earlier through advanced analytical approaches integrating longitudinal biomarker patterns and individualized risk factors.

This case underscores the broader need for next-generation decision-support tools capable of interpreting complex multiparametric laboratory profiles within demographic, behavioral, and clinical contexts. Aima Diagnostics is focused on developing AI-based methodologies aligned with this paradigm, aiming to enhance early detection, risk stratification, and clinical decision support.

Author: Line Strøm
Published: March 14, 2026 



References

1. U.S. Department of Justice. Epstein Files Transparency Act Disclosures. January–March 2026.
2. https://www.justice.gov/epstein
3. The New York Times. Epstein Medical Records Reveal Chronic Low Testosterone and STDs. March 2026.
4. STAT News. From VIP Care to Ethical Breaches: Epstein’s Medical Files. February 2026.
5. MedPage Today. Lab Results in Epstein Files Show Long-Standing Hypogonadism. March 2026.
6. Endocrine Society Clinical Practice Guideline. Testosterone Therapy in Men With Hypogonadism. 2025 update.
7. Travison TG et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102(4):1161–1173.
8. Travison TG et al. A Population-Level Decline in Serum Testosterone Levels in American Men. J Clin Endocrinol Metab.2007;92(1):196–202.

Contact for collaboration and scientific inquiries
aimamed.ai | info@aimamed.ai